10 results about "Trial drug" patented technology

This invention discloses a clinical trial drug cabinet and a clinical trial drug management method. The clinical trial drug cabinet includes a connected cabinet body and a cabinet door, with the interior of the cabinet body and the cabinet door forming a storage space. A weighing platform divides the storage space into multiple layers of clinical trial drug storage spaces. Each layer of clinical trial drug storage space is equipped with an electronic tag reader. By cooperating with the weighing platform and the electronic tag reader, it is possible to determine which clinical trial drug is currently being placed in or taken out of the cabinet, as well as the original storage space where the clinical trial drug was placed, or from which clinical trial drug was taken out. This effectively avoids drug management chaos and improves drug storage and retrieval efficiency.

The application discloses a kind of based on artificial intelligence's pharmaceutical clinical test safety evaluation method, comprising the following steps: collecting heterogeneous clinical survival data with deletion characteristics and time series drift characteristics, and constructing original survival data set;Based on propensity score model and survival outcome model, implement deletion correction, obtain individual non-compliance risk score;Through stratified weighting rule and two-side order-preserving prediction mechanism, calibrate and update individual risk prediction interval;Calculate individual risk upper and lower bound probability, define three-domain risk threshold rule, generate real-time risk decision result through three-domain decision mapping and dynamically evaluate overall safety trend.The application improves the robustness and interpretability of clinical safety risk decision.

This invention belongs to the field of biomedicine, specifically relating to the application of APOL2 (Apolipoprotein L2) inhibitors in the preparation of products for treating liver fibrosis. The inventors isolated a series of natural tetrodopane-type diterpenes from *Euphorbia pekinensis*, a plant in the Euphorbiaceae family. Anti-liver fibrosis-related activity tests on this series of diterpenes revealed that they significantly inhibited the expression of fibronectin, type I collagen, and α-smooth muscle actin in LX-2 cells. In animal studies, their therapeutic effect was superior to that of pirfenidone, a phase II clinical trial drug for treating liver fibrosis, and they showed no significant toxicity. Mechanistic studies showed that TD1 is an APOL2 inhibitor, and knocking out APOL2 protein in vivo can alleviate the progression of liver fibrosis. In summary, this series of tetrodopane-type diterpenes, especially TD1, shows promise as a candidate drug for treating liver fibrosis and provides a new target for researching novel drugs for treating liver fibrosis.

This invention discloses an intelligent management method and system applicable to drug clinical trials, relating to the field of drug clinical trial management technology. It includes collecting raw project activity records containing information such as trial site number and subject identification from the drug clinical trial execution system to form a collection. This collection undergoes multi-dimensional structured processing to generate a unified project view comprising subject time-series activity logs, trial site operational status snapshots, clinical document association networks, and key event sequences. Compliance modeling, effectiveness assessment, compliance checks, and logical verification are performed on the four types of views respectively. After generating corresponding specialized results, these are input into an intelligent analysis model for fusion and deduction, ultimately outputting a comprehensive project report including project risk warnings, process deviation location, and resource gap alerts. This invention achieves multi-dimensional integration and specialized fusion analysis of drug clinical trial data, optimizing the data analysis and application methods of clinical trial management.

This invention discloses an intelligent management method and system applicable to drug clinical trials, relating to the field of drug clinical trial management technology. It includes collecting raw project activity records containing information such as trial site number and subject identification from the drug clinical trial execution system to form a collection. This collection undergoes multi-dimensional structured processing to generate a unified project view comprising subject time-series activity logs, trial site operational status snapshots, clinical document association networks, and key event sequences. Compliance modeling, effectiveness assessment, compliance checks, and logical verification are performed on the four types of views respectively. After generating corresponding specialized results, these are input into an intelligent analysis model for fusion and deduction, ultimately outputting a comprehensive project report including project risk warnings, process deviation location, and resource gap alerts. This invention achieves multi-dimensional integration and specialized fusion analysis of drug clinical trial data, optimizing the data analysis and application methods of clinical trial management.

This invention belongs to the field of pharmaceutical technology and discloses the inhibitory effects and mechanisms of action of sclerotinib on lung cancer cells, cervical cancer cells, and ovarian cancer cells. Compared with the currently available broad-spectrum antitumor drug fluorouracil, sclerotinib exhibits superior antitumor properties. In-depth research revealed that sclerotinib acts on the novel protein STAT3 in cancer treatment, inhibiting STAT3 phosphorylation and preventing phosphonate-modified protein dimers from entering the cell nucleus to initiate transcription. Furthermore, sclerotinib inhibits the downstream anti-apoptotic protein BCL-2 of STAT3, synergistically inhibiting tumor cell proliferation. In this study, based on the half-maximal inhibitory concentration (IC50) results of sclerotinib against lung cancer cells A549, cervical cancer cells HeLa, and ovarian cancer cells A2780, we directly verified the anticancer target of sclerotinib through experiments, elucidated its anticancer mechanism, and provided theoretical and experimental basis for its entry into preclinical and clinical trials.

Aptamers are single-stranded RNA or DNA molecules that bind to target molecules by forming complex three-dimensional structures. Their target molecules vary widely—including proteins, peptides, carbohydrates, lipids, small compounds, and metal ions—and because of their strong binding affinity and high specificity, aptamers have been put to practical use in fields such as therapeutics, diagnostics, and separation technologies. As pharmaceuticals, the world's first aptamer drug, Macugen®, was approved in the United States in 2004 as a treatment for neovascular age-related macular degeneration, and several other aptamers are now in clinical development. Research is also progressing on their use as tools in drug delivery systems (DDS), and the importance of aptamers in the pharmaceutical field is expected to continue growing. In this article, we provide an overview of aptamer acquisition methods and optimization strategies for therapeutic use, and introduce the latest developments in aptamer-based drugs currently in clinical trials.

The invention relates to the technical field of medical care informatics, in particular to an intelligent drug clinical test scheme generation method and system.The method comprises the steps that multi-source data of candidate molecules is received and subjected to standardization processing, and a standardized data set is obtained; retrieving the associated literature based on the standardized data set to obtain a target evidence quality report; retrieving measured data of the same-target reference drug based on the standardized data set to obtain a composite prediction data structure; taking the target evidence quality report and the credibility label in the composite prediction data structure as explicit constraints, generating clinical test parameters of candidate molecules, and obtaining a preliminary I-stage clinical test scheme; and performing comprehensive feasibility scoring on the I-stage clinical test scheme, and outputting a final intelligent drug clinical test scheme. According to the method, the clinical parameters have traceable information quality basis, the generated test scheme carries confidence level description, and the transparency and the verifiability of clinical development decisions can be improved.